Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry

Affiliations

¹ From the Department of Medicine (Cardiology), Duke Clinical Research Institute, Durham, NC (A.M.N., E.D.P., S.L., T.Y.W. M.G.N.); Department of Epidemiology, University of Iowa (J.G.R.); Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (V.L.R.); Washington University, St. Louis, MO (A.C.G.); VA Medical Center and Baylor College of Medicine, Houston, TX (S.V.); Department of Medicine, Emory University, Atlanta, GA (P.W.F.W.); Sanofi Pharmaceuticals, Bridgewater, NJ (L.V.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (J.E.). navar006@dm.duke.edu.
² From the Department of Medicine (Cardiology), Duke Clinical Research Institute, Durham, NC (A.M.N., E.D.P., S.L., T.Y.W. M.G.N.); Department of Epidemiology, University of Iowa (J.G.R.); Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (V.L.R.); Washington University, St. Louis, MO (A.C.G.); VA Medical Center and Baylor College of Medicine, Houston, TX (S.V.); Department of Medicine, Emory University, Atlanta, GA (P.W.F.W.); Sanofi Pharmaceuticals, Bridgewater, NJ (L.V.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (J.E.).

Multicenter Study

Ann Marie Navar et al. Circ Cardiovasc Qual Outcomes. 2018 Mar.

. 2018 Mar;11(3):e004249.

doi: 10.1161/CIRCOUTCOMES.117.004249.

¹ From the Department of Medicine (Cardiology), Duke Clinical Research Institute, Durham, NC (A.M.N., E.D.P., S.L., T.Y.W. M.G.N.); Department of Epidemiology, University of Iowa (J.G.R.); Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (V.L.R.); Washington University, St. Louis, MO (A.C.G.); VA Medical Center and Baylor College of Medicine, Houston, TX (S.V.); Department of Medicine, Emory University, Atlanta, GA (P.W.F.W.); Sanofi Pharmaceuticals, Bridgewater, NJ (L.V.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (J.E.). navar006@dm.duke.edu.
² From the Department of Medicine (Cardiology), Duke Clinical Research Institute, Durham, NC (A.M.N., E.D.P., S.L., T.Y.W. M.G.N.); Department of Epidemiology, University of Iowa (J.G.R.); Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (V.L.R.); Washington University, St. Louis, MO (A.C.G.); VA Medical Center and Baylor College of Medicine, Houston, TX (S.V.); Department of Medicine, Emory University, Atlanta, GA (P.W.F.W.); Sanofi Pharmaceuticals, Bridgewater, NJ (L.V.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (J.E.).

No abstract available

Keywords: Hydroxymethylglutaryl-CoA reductase inhibitors; cardiovascular disease; drug-related side effects and adverse reactions; nocebo effect.

References

1. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561. - PubMed
1. Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med. 2008;23:1182–1186. - PMC - PubMed
1. Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7:472–483. - PubMed
1. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ. 2014;349:g3743. - PMC - PubMed
1. Navar AM, Wang TY, Goldberg AC, Robinson JG, Roger VL, Wilson PF, Virani SS, Elassal J, Lee LV, Webb LE, Peterson E. Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) Registry. Am Heart J. 2015;170:865–871. - PubMed